Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.

Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also contemplated.

Disclosed herein are methods for treating eosinophilic oesophagitis with corticosteroids. The methods for treating eosinophilic oesophagitis disclosed herein result in reduced corticosteroid side effects, e.g. candidiasis. Dosages, formulations, and methods for administration of corticosteroids are provided.

The present disclosure provides for palonosetron formulations, such as aerosol formulations of palonosetron for pulmonary delivery. Also provided are uses of the formulation, such as reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, or surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations.

The present invention relates to intranasal pharmaceutical compositions comprising cyclobenzaprine or salts thereof for the treatment or management of muscle spasms in musculoskeletal diseases and/or painful physical symptoms in neurological diseases. In particular, the invention relates to intranasal pharmaceutical compositions comprising cyclobenzaprine or salts thereof and one or more pharmaceutically acceptable excipients.

In an embodiment, a metered dose inhaler (MDI) training device is provided herein. The MDI training device may include a housing having an inhalation port, an opening for receiving ambient air, the inhalation port and the opening are fluidly connected to provide an air flow channel, and a valve associated with the air flow channel, the valve having an opened state and a closed state, and an actuation member, wherein the valve is not allowed to enter the opened state if the actuation member is actuated prior to inhalation through the inhalation port.

Provided herein are methods for treating, preventing, minimizing and/or substantially inhibiting inflammation associated with a respiratory virus such as COVID-19 and/or acute respiratory distress syndrome (ARDS), comprising administering to the lungs of a subject, by inhalation, a composition comprising an effective amount of an active agent such as a corticosteroid (for example, loteprednol etabonate (LE)). Also provided are pharmaceutical compositions comprising an active agent, such as a corticosteroid (for example, loteprednol etabonate (LE)) in an amount effective to treat, minimize and/or substantially inhibit inflammation associated with the respiratory virus, such as COVID-19 and/or ARDS.

The present invention is directed to methods of treating nasal and/or ophthalmic diseases, symptoms, or disorders that are therapeutically responsive to corticosteroid therapy by delivering aqueous solution formulations comprising a corticosteroid to nasal and ophthalmic tissues. The invention is also directed to methods, systems, devices, and compositions for delivering aqueous solution formulations comprising a corticosteroid and an antihistamine to nasal and ophthalmic tissues.

The present invention generally relates to an aerosol formulation comprising formoterol, beclomethasone dipropionate and glycopyrronium bromide, said formulation being contained in a coated can, particularly useful for the use in a pressurised metered dose inhaler for the treatment of respiratory diseases.

An inhaler comprising a valve having a valve volume of no more than 40 micro liters and a valve having a first layer comprising a silane and a second layer comprising a polyfluoropolyether silane—and albuterol.